These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 6221055

  • 1. Studies on platelet aggregation inhibitors in vivo. X. Relationship to thrombolysis.
    Ambrus JL, Ambrus CM, Sharma SD, Suh OW, Gastpar H.
    J Med; 1982; 13(5-6):365-71. PubMed ID: 6221055
    [Abstract] [Full Text] [Related]

  • 2. Mechanism of the potentiation of thrombolysis by pentoxifylline (Trental).
    Ambrus JL, Ambrus CM, Mahfzah M, Markus JA, Klein E, Gastpar H.
    J Med; 1987; 18(5-6):265-76. PubMed ID: 3505256
    [Abstract] [Full Text] [Related]

  • 3. Study of platelet aggregation in vivo. III. Effect of pentoxifylline.
    Gastpar H, Ambrus JL, Ambrus CM, Spavento P, Weber FJ, Thurber LE.
    J Med; 1977; 8(3-4):191-7. PubMed ID: 407320
    [Abstract] [Full Text] [Related]

  • 4. The role of fibrinolysis in the therapy of peripheral vascular disease.
    Ambrus CM, Ambrus JL, Gastpar H, Sharma SD, Suh OW, Moore RH, Williams P.
    Angiology; 1984 Jul; 35(7):436-42. PubMed ID: 6235758
    [Abstract] [Full Text] [Related]

  • 5. Potentiation of thrombolytic therapy by enzyme combinations and with aspirin or pentoxifylline.
    Ambrus JL, Ambrus CM, Stadler S, Toumbis C, Markus G.
    J Med; 1994 Jul; 25(3-4):145-61. PubMed ID: 7996060
    [Abstract] [Full Text] [Related]

  • 6. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
    Dewerchin M, Lijnen HR, Stassen JM, De Cock F, Quertermous T, Ginsberg MH, Plow EF, Collen D.
    Blood; 1991 Aug 15; 78(4):1005-18. PubMed ID: 1831057
    [Abstract] [Full Text] [Related]

  • 7. In vitro potentiation of urokinase-activated lysis of human fibrin clots.
    Singh K, Vézina C.
    J Med; 1974 Aug 15; 5(6):297-302. PubMed ID: 4528600
    [No Abstract] [Full Text] [Related]

  • 8. Studies on platelet aggregation in vivo. VII: Effect of pentoxyfylline on circulating tumor cells.
    Gastpar H, Ambrus JL, Ambrus CM.
    J Med; 1978 Aug 15; 9(3):265-8. PubMed ID: 283171
    [Abstract] [Full Text] [Related]

  • 9. Studies on vasoocclusive crisis of sickle cell disease. I. Effect of pentoxifylline.
    Ambrus JL, Ambrus CM, Gastpar H, Bannerman R, Bettigole R, Friedman S.
    J Med; 1979 Aug 15; 10(6):445-56. PubMed ID: 299453
    [Abstract] [Full Text] [Related]

  • 10. Pentoxifylline does not interfere with stable coumarin anticoagulant therapy: a clinical study.
    Ingerslev J, Mouritzen C, Stenbjerg S.
    Pharmatherapeutica; 1986 Aug 15; 4(9):595-600. PubMed ID: 3763653
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O, Rijken DC, Collen D.
    Thromb Haemost; 1981 Jun 30; 45(3):225-9. PubMed ID: 7025339
    [Abstract] [Full Text] [Related]

  • 12. Effect of pentoxifylline on platelet aggregation.
    Nenci GG, Gresele P, Agnelli G, Ballatori E.
    Pharmatherapeutica; 1981 Jun 30; 2(8):532-8. PubMed ID: 7255510
    [Abstract] [Full Text] [Related]

  • 13. Effect of phosphodiesterase inhibitors on platelet aggregation and tumor metastasis.
    Ambrus JL, Ambrus CM, Gastpar H.
    Ric Clin Lab; 1981 Jun 30; 11 Suppl 1():197-207. PubMed ID: 6324323
    [Abstract] [Full Text] [Related]

  • 14. Drug stimulated prostacyclin release.
    Weithmann KU.
    Ric Clin Lab; 1981 Jun 30; 11 Suppl 1():209-14. PubMed ID: 6324324
    [Abstract] [Full Text] [Related]

  • 15. Studies on platelet aggregation inhibitors in vivo. VIII. Effect of pentoxifylline on spontaneous tumor metastasis.
    Gordon S, Witul M, Cohen H, Sciandra J, Williams P, Gastpar H, Murphy GP, Ambrus JL.
    J Med; 1979 Jun 30; 10(6):435-43. PubMed ID: 233697
    [Abstract] [Full Text] [Related]

  • 16. [A hybrid molecule of pro-urokinase and a fibrin-specific, monoclonal antibody fragment is a more effective thrombolytic agent than pro-urokinase in vitro and in vivo].
    Bode C, Eberle T, Runge M, Haber E, Kübler W.
    Verh Dtsch Ges Inn Med; 1990 Jun 30; 96():1-3. PubMed ID: 2128723
    [No Abstract] [Full Text] [Related]

  • 17. Inhibitor-resistant tissue-type plasminogen activator: an improved thrombolytic agent in vitro.
    Shohet RV, Spitzer S, Madison EL, Bassel-Duby R, Gething MJ, Sambrook JF.
    Thromb Haemost; 1994 Jan 30; 71(1):124-8. PubMed ID: 8165630
    [Abstract] [Full Text] [Related]

  • 18. Substrate composition and the effect of epsilon-aminocaproic acid on tissue plasminogen activator and urokinase-induced fibrinolysis.
    Thorsen S, Astrup T.
    Thromb Diath Haemorrh; 1974 Dec 31; 32(2-3):306-24. PubMed ID: 4281113
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody.
    Bode C, Runge M, Eberle T, Freitag M, Kübler W, Haber E.
    Trans Assoc Am Physicians; 1989 Dec 31; 102():7-12. PubMed ID: 2517856
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.